Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

ClinicalTrials.gov ID: NCT03225846

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03225846. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).

Study identification

NCT ID: NCT03225846
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Wave Life Sciences USA, Inc.; Industry
Enrollment: 88 participants

Conditions and interventions

Conditions

Huntington's Disease

Interventions

WVE-120102 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 25 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 17, 2017 (Actual)
Primary completion: May 10, 2021 (Actual)
Completion: May 10, 2021 (Actual)
Last update posted: Apr 25, 2022

2017 – 2021

United States locations

U.S. sites: 5
U.S. states: 4
U.S. cities: 5

Facility	City	State	ZIP	Site status
University of California San Diego	La Jolla	California	92037-0949	—
University of California Davis Medical Center	Sacramento	California	95817	—
Massachusetts General Hospital	Boston	Massachusetts	02129	—
The Ohio State University	Columbus	Ohio	43210	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03225846, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 25, 2022 · Synced Nov 15, 2026